Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Demographic and clinical characteristics of the study population. Clinical and Biochemical | NBMD, n=213 | LBMD, n=243 | p-value | Characteristics | Median (P25-P75) | Median (P25-P75): Vitamin D intake, UI/day | 111 (65-170) | 103 (69-158) | 0.3891

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Multiple reported designs.

Multiple reported designs

More than one design is explicitly reported; examine the supporting methods.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This study is a cross-sectional analysis using a subsample from the third wave (2017 to 2019) of the Health Worker Cohort Study (HWCS).

Source: Methods.

Women were selected based on the following inclusion criteria: ≥45 years old, menopause confirmed (12 consecutive months without menstruation), and available BMD measurements.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

SHBG and APOA1 as serum biomarkers for low bone mineral density in Mexican postmenopausal women: a random forest-based analysis

Multiple reported designs · Frontiers in Endocrinology · 2026

Original publication title

SHBG and APOA1 as serum biomarkers for low bone mineral density in Mexican postmenopausal women: a random forest-based analysis

Diana I Aparicio-Bautista; Adriana Becerra-Cervera; Berenice Rivera-Paredez; Rogelio F Jiménez-Ortega; Tania V López-Pérez; Jorge Salmerón; J. Pablo Reyes-Grajeda; Alberto Hidalgo-Bravo; Rafael Velázquez-Cruz

Copyright © 2026 Aparicio-Bautista, Becerra-Cervera, Rivera-Paredez, Jiménez-Ortega, López-Pérez, Salmerón, Reyes-Grajeda, Hidalgo-Bravo and Velázquez-Cruz.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The combination of APOA1 and SHBG correlates better with the risk of bone loss than the performance of single biomarkers in postmenopausal women. Further validation in a larger cohort is necessary to confirm these results.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To validate a set of 6 proteins as potential minimally invasive serum biomarkers, Gelsolin (GSN), Sex Hormone-Binding Globulin (SHBG), Apolipoprotein A1 (APOA1), Apolipoprotein A2 (APOA2), Ryanodine Receptor 1 (RYR1), and Ryanodine Receptor 3 (RYR3), for diagnosing low BMD in postmenopausal women. We also investigated whether a combination of these proteins can provide more informative insights into the risk of having low BMD compared to individual biomarkers.

Source: Objective

Abstract: What methods does the paper describe?

The enzyme-linked immunosorbent assay was carried out to measure the concentrations of these proteins in 456 serum samples from postmenopausal Mexican women with normal or low BMD.

Source: Methods

Abstract: Results

A random forest classifier demonstrated that SHBG and APOA1 are the most effective biomarkers for discriminating between women with normal or low BMD, with notable high sensitivity (86%), specificity (75%), precision (92%), and overall performance (89.32%).

Source: Results

Abstract: Conclusions

The combination of APOA1 and SHBG correlates better with the risk of bone loss than the performance of single biomarkers in postmenopausal women. Further validation in a larger cohort is necessary to confirm these results.

Source: Conclusions
Authors’ abstract

Background

Osteoporosis is a major health issue that has implications worldwide, both clinically and socioeconomically. Therefore, searching for informative bone health biomarkers that provide early information on bone changes and assess treatment efficacy is essential. Previously, our group used label-free proteomics and bioinformatic approaches to analyze the serum proteomic profile of postmenopausal women with normal bone mineral density (BMD), osteopenia, and osteoporosis. Based on their role in bone metabolism and literature review, a panel of 12 candidate serum biomarkers for low BMD was proposed.

Objective

To validate a set of 6 proteins as potential minimally invasive serum biomarkers, Gelsolin (GSN), Sex Hormone-Binding Globulin (SHBG), Apolipoprotein A1 (APOA1), Apolipoprotein A2 (APOA2), Ryanodine Receptor 1 (RYR1), and Ryanodine Receptor 3 (RYR3), for diagnosing low BMD in postmenopausal women. We also investigated whether a combination of these proteins can provide more informative insights into the risk of having low BMD compared to individual biomarkers.

Methods

The enzyme-linked immunosorbent assay was carried out to measure the concentrations of these proteins in 456 serum samples from postmenopausal Mexican women with normal or low BMD.

Results

A random forest classifier demonstrated that SHBG and APOA1 are the most effective biomarkers for discriminating between women with normal or low BMD, with notable high sensitivity (86%), specificity (75%), precision (92%), and overall performance (89.32%).

Conclusions

The combination of APOA1 and SHBG correlates better with the risk of bone loss than the performance of single biomarkers in postmenopausal women. Further validation in a larger cohort is necessary to confirm these results.

Publication and source details

Original title: SHBG and APOA1 as serum biomarkers for low bone mineral density in Mexican postmenopausal women: a random forest-based analysis

Diana I Aparicio-Bautista; Adriana Becerra-Cervera; Berenice Rivera-Paredez; Rogelio F Jiménez-Ortega; Tania V López-Pérez; Jorge Salmerón; J. Pablo Reyes-Grajeda; Alberto Hidalgo-Bravo; Rafael Velázquez-Cruz

Frontiers in Endocrinology · 2026

* Correspondence: Alberto Hidalgo-Bravo, dr_genetica@yahoo.com; Rafael Velázquez-Cruz, rvelazquez@inmegen.gob.mx

†Present address: Adriana Becerra-Cervera, Dirección General de Atención a la Salud (DGAS)-UNAM, Ciudad de México, Mexico

Copyright © 2026 Aparicio-Bautista, Becerra-Cervera, Rivera-Paredez, Jiménez-Ortega, López-Pérez, Salmerón, Reyes-Grajeda, Hidalgo-Bravo and Velázquez-Cruz.2026Aparicio-Bautista, Becerra-Cervera, Rivera-Paredez, Jiménez-Ortega, López-Pérez, Salmerón, Reyes-Grajeda, Hidalgo-Bravo and Velázquez-Cruzhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This work was funded by the Consejo Nacional de Ciencia y Tecnología (Grant Ciencia de Frontera CF2019 -102962) and received partial funding from Instituto Nacional de Medicina Genómica (314-07/2017/I and 266-17/2016/I). A.B.-C. is supported by a Postdoctoral Fellowship from the Consejo Nacional de Humanidades, Ciencia y Tecnología (CONAHCYT-Estancia Postdoctoral de Incidencia Inicial 2022 with CVU 508876).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:58:21.210438+00:00

DOI: 10.3389/fendo.2026.1824756 · PMC13485816